Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Gains from Sales and Divestitures (2016)

Bone Biologics (BBLG) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with -$791139.0 as the latest value for Q4 2016.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to -$791139.0 in Q4 2016 year-over-year; TTM through Dec 2016 was -$791139.0, a N/A change, with the full-year FY2016 number at -$791139.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was -$791139.0 for Q4 2016 at Bone Biologics.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of -$791139.0 in Q4 2016 to a low of -$791139.0 in Q4 2016.